658MO Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040

Soulieres, D.; Harrington, K.j.; Le Tourneau, C.; Silva, J.d.; Licitra, L.f.; Ahn, M-J.; Soria, A.; Machiels, J-P.; Mach, Nicolas; Mehra, R.; Burtness, B.; Lin, J.; Lerman, N.; Gumuscu, B.; Cohen, E.e.w.

doi:10.1016/j.annonc.2022.07.782

Conference presentation

English

658MO Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040

ContributorsSoulieres, D.; Harrington, K.j.; Le Tourneau, C.; Silva, J.d.; Licitra, L.f.; Ahn, M-J.; Soria, A.; Machiels, J-P.; Mach, Nicolas; Mehra, R.; Burtness, B.; Lin, J.; Lerman, N.; Gumuscu, B.; Cohen, E.e.w.

Presented atEuropean Society for Medical Oncology (ESMO) Congress, Paris, 9-13 septembre 2022

Publication date2022-09

NotePublié dans : Annals of oncology, 2022, 33, S7, S843

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Immunothérapie (654)

Citation (ISO format)

SOULIERES, D. et al. 658MO Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040. In: European Society for Medical Oncology (ESMO) Congress. Paris. 2022. doi: 10.1016/j.annonc.2022.07.782

Summary

OA OTHER

Identifiers

PID : unige:175805
DOI : 10.1016/j.annonc.2022.07.782

Additional URL for this publicationhttps://linkinghub.elsevier.com/retrieve/pii/S0923753422026333

43views

0downloads

Creation06/12/2023 14:55:06

First validation20/03/2024 15:49:13

Update time08/10/2024 17:14:44

Status update08/10/2024 17:14:44

Last indexation01/11/2024 09:58:18

Archive ouverte UNIGE

658MO Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040

Technical informations